NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

HEU Cluster 6 – HORIZON-CL6-2024-BIODIV-02 – Number of submitted proposals

Published on | 2 months ago

Programmes Agro-Food, Environment  

Call HORIZON-CL6-2024-BIODIV-02_stage2 has closed on 17/09/2024.

21 proposals have been submitted.

The breakdown per topic is:

HORIZON-CL6-2024-BIODIV-02-1-two-stage: 6 proposals

HORIZON-CL6-2024-BIODIV-02-2-two-stage: 8 proposals

HORIZON-CL6-2024-BIODIV-02-3-two-stage: 7 proposals

Evaluation results are expected to be communicated in January 2025

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1484 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.